Biodexa Pharmaceuticals PLC has announced the commencement of its Phase 3 clinical trial for eRapa, a proprietary encapsulated form of rapamycin, aimed at treating familial adenomatous polyposis (FAP). This trial follows a successful Phase 2 trial, which showed a median decrease in overall polyp burden of 29% and a non-progression rate of 89% at 12 months in the dosage regimen selected for Phase 3. The double-blind, placebo-controlled trial involves 168 patients and is being conducted across approximately 30 clinical sites in the U.S. and Europe. The study is supported by a $20 million grant from the Cancer Prevention & Research Institute of Texas, with management of the U.S. and European components by LumaBridge and Precision for Medicine LLC, respectively. The results of the Phase 3 trial are yet to be presented.